Ipsen Upgrades 2026 Guidance on 23.5% Sales Growth, Positive Phase III Readouts, and Pipeline-Building Acquisitions
核心洞察
Ipsen reported H1 2026 total sales of €2.19 billion, representing 23.5% growth at constant exchange rates, and upgraded full-year 2026 sales growth guidance to greater than 20.0% at CER.
Positive Phase III results for Dysport in both episodic and chronic migraine (搜索) prevention make it the first botulinum toxin to demonstrate efficacy across both indications in pivotal trials.
The Phase IIIb ELSPIRE study of Iqirvo in primary biliary cholangitis (搜索) met its primary endpoint, with 85% of patients achieving ALP normalization at Week 52 versus 23% on placebo (p<0.0001).
Ipsen delivered a strong first-half 2026 performance, reporting total sales of €2,190.2 million — a 23.5% increase at constant exchange rates (CER) and 20.4% as reported — driven by growth across all three therapeutic areas. The Paris-based global specialty-care biopharmaceutical company also upgraded its full-year 2026 financial guidance, reflecting confidence in its accelerating portfolio and expanding late-stage pipeline.
"Our excellent first-half performance demonstrates the strength of Ipsen's strategy, with all three therapeutic areas contributing to growth and the portfolio beyond Somatuline continuing to accelerate," said David Loew, Chief Executive Officer, Ipsen. "This momentum enables us to upgrade our 2026 guidance while continuing to invest in innovation and future growth."
Financial Performance and Upgraded Guidance
Core operating income reached €844.9 million, growing 28.8% as reported, with a core operating margin of 38.6% of total sales — an increase of 2.5 percentage points compared to the prior-year period. Core consolidated net profit rose 19.6% to €607.7 million, with core earnings per share (fully diluted) reaching €7.33, up 20.7% from €6.07 in H1 2025. Free cash flow surged 34.9% to €651.7 million, and the company closed the period with a net cash position of €1,004.9 million.
Based on this momentum, Ipsen upgraded its FY 2026 guidance: total sales growth is now expected to exceed 20.0% at CER, up from the prior guidance of greater than 13.0%. The core operating margin is now projected above 37.0% of total sales, compared with the previous target of greater than 35.0%. The upgraded margin guidance incorporates additional R&D expenses from anticipated early and mid-stage external innovation opportunities and assumes the dilutive impact of the acquisitions of Memo Therapeutics AG and Kartos Therapeutics (搜索).
Dysport Phase III Success in Migraine (搜索) Prevention
Ipsen announced positive topline Phase III results from the BEOND migraine (搜索) program in July, with Dysport (abobotulinumtoxinA) meeting the primary endpoint in both the episodic (E-BEOND) and chronic (C-BEOND) trials. The studies demonstrated statistically significant reductions in monthly migraine days versus placebo, making Dysport the first botulinum toxin to show efficacy in Phase III trials across both episodic and chronic migraine prevention.
Dysport was well tolerated across both trials, with a safety profile consistent with its established use and no new safety signals identified. Ipsen intends to submit these data to regulatory authorities, with detailed results to be presented at a future scientific congress.
Iqirvo Demonstrates Compelling Efficacy in Primary Biliary Cholangitis (搜索)
The Phase IIIb ELSPIRE study of Iqirvo (elafibranor) in primary biliary cholangitis (搜索) (PBC) delivered positive topline results in July. The study met its primary endpoint: 85% of patients receiving Iqirvo achieved alkaline phosphatase (ALP) normalization at Week 52, compared with 23% of patients on placebo (p<0.0001). The safety profile remained consistent with previous studies, with no new safety signals identified.
ELSPIRE evaluated patients with ALP levels of 1–1.67x the upper limit of normal (ULN), and the results support the potential to significantly expand the addressable population for Iqirvo. Ipsen plans to submit the data to regulatory authorities and present findings at an upcoming scientific congress.
Pipeline Setback: Bylvay in Biliary Atresia (搜索)
Not all pipeline news was positive. Ipsen announced that the Phase III BOLD trial evaluating Bylvay (odevixibat) versus placebo in patients with biliary atresia (搜索) who had undergone a Kasai hepatoportoenterostomy did not meet its primary endpoint of improved native liver survival. Topline safety data remained consistent with odevixibat's well-established profile in its approved indications, with no new safety signals identified.
External Innovation: Two Strategic Acquisitions
Ipsen significantly strengthened its late-stage pipeline through two strategic transactions. The company completed its acquisition of Memo Therapeutics AG in July, gaining potravitug, a Phase II antibody targeting BK polyomavirus (搜索) (BKPyV) — a frequent cause of nephropathy, graft loss, and transplant failure in kidney transplant recipients. Potravitug received FDA Fast Track designation in 2023 and EU Orphan Drug designation in 2025. Memo Therapeutics AG shareholders received €200 million upfront, with the potential for total consideration exceeding €700 million through development, regulatory, and sales milestones.
Additionally, Ipsen announced an agreement to acquire Kartos Therapeutics (搜索), a clinical-stage biopharmaceutical company centered on navtemadlin, a Phase III oral MDM2 (搜索) inhibitor for myelofibrosis (搜索). Navtemadlin is designed to restore p53 tumor-suppressor activity in patients with a suboptimal response to ruxolitinib. Top-line data from the registrational POIESIS trial are expected in 2027. Under the terms of the agreement, Kartos shareholders will receive $450 million upfront and may be eligible for up to $1.3 billion in milestone payments, with closing anticipated by the end of Q3 2026, subject to customary conditions.
"Importantly, we have significantly strengthened our late-stage pipeline in the first half, with positive Phase III lifecycle management readouts for Dysport in episodic and chronic migraine (搜索) and Iqirvo in primary biliary cholangitis (搜索), alongside the completed acquisition of Memo Therapeutics AG and the proposed acquisition of Kartos Therapeutics (搜索)," Loew said. "These transactions add two innovative clinical assets — navtemadlin and potravitug — with the potential to address significant unmet needs and create long-term value."
Early-Stage Innovation: Corabotase (搜索)
In May, Ipsen presented late-breaking Phase II data in glabellar lines for corabotase (搜索), its first-in-class recombinant neuroinhibitor (RNI). The data demonstrated a rapid onset of action, a statistically superior peak effect versus placebo at Week 4, and a clinically significant sustained duration of effect, outperforming both placebo and Dysport at Week 24. Corabotase has been recognized by the World Health Organization and the United States Adopted Name council as a novel botase molecule.